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Abstract
Background: Mild traumatic brain injury (mTBI) has a higher prevalence (more than 50%) of developing chronic
posttraumatic headache (CPTH) compared with moderate or severe TBI. However, the underlying neural mechanism
for CPTH remains unclear. This study aimed to investigate the inflammation level and cortical volume changes in
patients with acute PTH (APTH) and further examine their potential in identifying patients who finally developed
CPTH at follow-up.
Methods: Seventy-seven mTBI patients initially underwent neuropsychological measurements, 9-plex panel of
serum cytokines and MRI scans within 7 days post-injury (T-1) and 54 (70.1%) of patients completed the same
protocol at a 3-month follow-up (T-2). Forty-two matched healthy controls completed the same protocol at T-1
once.
Results: At baseline, mTBI patients with APTH presented significantly increased GM volume mainly in the right
dorsal anterior cingulate cortex (dACC) and dorsal posterior cingulate cortex (dPCC), of which the dPCC volume can
predict much worse impact of headache on patients’ lives by HIT-6 (β = 0.389, P = 0.007) in acute stage. Serum
levels of C-C motif chemokine ligand 2 (CCL2) were also elevated in these patients, and its effect on the impact of
headache on quality of life was partially mediated by the dPCC volume (mean [SE] indirect effect, 0.088 [0.0462],
95% CI, 0.01–0.164). Longitudinal analysis showed that the dACC and dPCC volumes as well as CCL2 levels had
persistently increased in patients developing CPTH 3 months postinjury.
Conclusion: The findings suggested that structural remodelling of DMN brain regions were involved in the
progression from acute to chronic PTH following mTBI, which also mediated the effect of inflammation processes
on pain modulation.
Trial registration: ClinicalTrial.gov ID: NCT02868684; registered 16 August 2016.
Keywords: Mild traumatic brain injury, Posttraumatic headache, Voxel-based morphometry, Inflammation effect
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Introduction
Traumatic brain injury (TBI) is a major global public
health problem that affects 50 million people each year,
and it is estimated that about half the world’s population
will have one or more TBIs over their lifetime [1, 2].
The US Centers for Disease Control and Prevention
reports that mild TBI is experienced in 70%–90% of
TBI-related emergency department (ED) visits [3]. Post
posttraumatic headache (PTH) is a high prevalence of
disabling trauma- and pain-related disorder [4, 5], and
may developed into the chronic pain in patients with
TBI [1, 2]. Unexpectedly, mild TBI (mTBI) is identified
as one of the most vulnerable risk to develop chronic
PTH (CPTH) (prevalence rate: 72.7%–77.9%), compared
with much server cases (moderate or severe TBI, prevalence rate: 29.3%–34.9%) [6]. Our recent study found
that acute PTH (APTH) following mTBI led to the disrupted functional connectivity between the periaqueductal grey (PAG) and default mode network (DMN). This
pain-related cognitive dysregulation may partially due to
the over-attention on brain injury-related symptom.
However, the underlying neurobiological basis and modulatory component remained unclear.
TBI can induce a multitude of inflammatory biomarkers
perpetuating the secondary injury to the brain [7, 8], which
upregulates central nerve system (CNS) excitability contributing to the generation and persistent of concomitant headache [9–11]. Multiple pain disorders have altered grey
matter volume (GMV) within the pain matrix [12, 13]. Notably, peripheral inflammatory cytokines/chemokines can
interact with multiple central pathways as a principal channel for inflammation-brain communication in the development of pain states [14, 15]. Considering the potential
effect of trauma-induced systemic inflammation on brain
cell reaction [16, 17], we hypothesized that the inflammatory cytokines level might lead to changes in pain perception via inflammation-brain mechanism [18, 19],
specifically by affecting cortical morphology alternations in
pain-related cognitive modulation following mTBI [20].
The present study investigated modifications of GM volume to identify those brain regions related to the emergence and persistence of pain condition known as PTH
following mTBI, and contrasted patients without PTH, in
addition to healthy controls. This study was aimed to
examine whether GMV changes mediated the relationship
between inflammation and PTH in acute mTBI patients.
Longitudinally, we hypothesized that both inflammatory
response and brain morphological alterations contributed
to those mTBI patients who finally developed into CPTH.
Material and methods
Participants

Seventy-seven patients (45 male, ages of 34.7 ± 12.2
years, education level of 8.6 ± 3.8 years) with mTBI and
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forty-two matched healthy controls (HC, 21 male, ages
of 35.3 ± 11.2 years, education level of 10.5 ± 5.2 years)
were recruited in the study (Clinical trial:
NCT02868684). All consecutive patients from the local
emergency department (ED) with non-contrast head CT
due to acute head trauma enrolled as the initial population. Inclusion criteria for mild TBI were based on the
World Health Organization’s Collaborating Centre for
Neurotrauma Task Force [21]. Mild TBI patients were
excluded:1) history of a previous brain injury, preexisting
headache, neurological disease, long-standing psychiatric
condition, or concurrent substance or alcohol abuse, 2)
structural abnormality on conventional neuroimaging
(CT and MRI), 3) intubation and/or presence of a skull
fracture and administration of sedatives, 4) the manifestation of mild TBI due to medications by other injuries
(e.g., systemic injuries, facial injuries, or spinal cord injury), 5) other problems (e.g., psychological trauma, language barrier, or coexisting medical conditions), 6)
caused by penetrating craniocerebral injury. Patients
with structural abnormality on conventional neuroimaging and a premorbid condition, such as history of a previous brain injury, preexisting headache, neurological
disease, concurrent substance or alcohol abuse were excluded. MRI scanning for mTBI patients was originally
evaluated within 7 days post-injury (acute phase) and
follow-up at 3 month post-injury (chronic phase). Measures for patients were circulating markers of inflammation, clinical and neuropsychological assessments within
48 h of MRI scans.
MTBI patients were divided into two groups based on
the presence of PTH at the acute stage (within 7 days
post-injury): mTBI with and without acute posttraumatic
headache (APTH) according to the Third Edition of the
International Classification of Headache Disorders (ICHD-3) [22]. If the headache persists for longer than 3
months after head trauma, it is described as the chronic/
persistent PTH (CPTH/PPTH).
Healthy subjects carefully screened for history of
acute/chronic pain, neurological or psychiatric disorder,
were also recruited. Forty-two age-, sex- and educationmatched healthy volunteers completed an identical neuroimaging scan and assessments at a single time point as
a control group. The study was approved by the local
ethics committee in accordance with the Declaration of
Helsinki. Written informed consent was obtained from
all participants. (see online supplementary eMethods).
Serum biomarker collection and assay

Serum samples for both patients and controls were
collected in the morning around 7–8 am. Sample were
aliquoted and stored at − 80 °C until the time of assay
after collection and centrifugation. Serum cytokine levels
(pg/mL) were measured using reagents on a Luminex

Niu et al. The Journal of Headache and Pain

(2020) 21:135

multiplex bead system (Luminex Austin, TX, USA). A
fluorescence detection laser optic system was used to
analyze binding of each individual protein on the microsphere simultaneously, which permits multiplexed
analysis of several analytes in one sample. Intra- and
inter-assay coefficients of variation observed for Luminex quantification were less than 20% and 25%, respectively. Samples with levels that were undetectable by the
assay were set to the value of 0.01 pg/mL. The criteria
for cytokines selection were mainly based on whether
it’s related to TBI or clinical symptoms such as PCS and
pain function [23, 24]. The cytokines included (i) the
archetypal pro-inflammatory cytokines: IL-1β, IL-6 and
IL-12, and the anti-inflammatory cytokines IL-4, IL-10;
(ii) chemokine (C-C motif) ligand 2 or monocyte chemoattractant protein-1(CCL2 or MCP-1) and member of
the CXC chemokine family (CXCL8) IL-8; (iii)
interferon-γ (IFN-γ); and (iv) tumor necrosis factor α
(TNF-α).
Clinical evaluations and pain symptom measurement

Clinical evaluations included post-injury days, duration
for both the posttraumatic amnesia (PTA) and loss of consciousness (LOC). Intensity of pain symptoms were
assessed by the Visual Analogue Scale (VAS, range 0–10)
[25]. The Pain VAS confines to patient-report (PR) measures including pain subscales for the current headache
and current general pain as well as mean, best and worst
levels of general pain intensity experienced in the preceding week. The VAS ranges from 0 to 10, with 0 meaning
“no pain at all” and 10 “the worst possible pain” and reliably tested in previous reports [26, 27]. The impact of
headache on patients’ lives was also evaluated with the
Short-Form Headache Impact Test (HIT-6) [28, 29].
Neuropsychological assessment

A comprehensive neuropsychological assessments included: i) Trail-Making Test Part A and Digit Symbol
coding score from the Wechsler Adult Intelligence Scale
III (WAIS-III) to examine cognitive information processing speed; ii) Forward Digit Span and Backward Digit
Span from the WAIS-III to assess immediate auditory
span, working memory, and executive function; iii)
Verbal Fluency Test to assess verbal fluency including
language ability, semantic memory and executive function; iv) Depression severity was assessed using the Beck
Depression Inventory (BDI-II); v) Posttraumatic stress
disorder (PTSD) Checklist - Civilian Version (PCL-C);
vi) Fatigue Severity Scale, Insomnia Severity Index. In
addition, post concussive symptoms (PCS) were measured with the Rivermead Post-Concussion Symptom
Questionnaire (RPQ) [30] consisting of 16 items, which
was specifically developed to assess the severity of symptoms experienced after brain injury.

Page 3 of 12

Image acquisition

The protocol for scanning included a non-contrast CT
scan for acute head injury. MRI scanning was conducted
on 3 T MRI scanner (GE 750) and included the T1weighted 3D BRAVO sequence, conventional T1- and
T2-weighted image, and susceptibility weighted imaging
(SWI) (see online supplementary eMethods).

MRI data processing

The T1-MRI images were processed using the Computational Anatomy Toolbox (CAT12) in Statistical Parametric Mapping 12 (SPM12; https://www.fil.ion.ucl.ac.uk/
spm/software/spm12/). Anatomical images were firstly
segmented into the gray matter, white matter, and cerebrospinal fluid (CSF), spatially normalized into the Montreal Neurological institute (MNI) template space, and
then smoothed with an isotropic Gaussian kernel of 8
mm full width at half maximum. Group differences on
GMV using the total intracranial volume, the white matter volume, age, and sex as covariants were performed
with a cluster forming (voxel-wise) threshold of uncorrected p < 0.001 and then corrected for multiple comparisons at the cluster level (p < 0.05, family-wise error
(FWE) rate correction). To explore the influence of depression on GMV, we repeated the above analyses of
between-group differences after adding the BDI-II score
as covariate. Absolute threshold masking was set at 0.1
to avoid edge effects between gray and white matter.
Based on the previous studies of pain-related diseases
[31], we performed region of interest (ROI) analysis
within the pain matrix including the anterior and posterior cingulate cortex, prefrontal cortex, insula, hippocampus, middle and inferior temporal gyrus, and thalamus,
according to the Brodmann template using Slice Viewer
in REST V1.8.

Mediation analysis

To examine whether regional GMV could mediate the
effect of inflammation cytokines on pain symptom in
the acute PTH, a mediation analysis was performed
by using the PROCESS tool [32] as implemented in
SPSS v.21. Firstly, a stepwise regression model was
used to calculate the odd ratio of the serum biomarker for pain symptom measurements in mTBI patients. Secondly, based on the results of the stepwise
regression analysis, resulting serum biomarker was entered as the independent variable, pain symptom measurements as the dependent variable. The mean GM
volume for each region showing significant group difference was tested separately as the mediator variable
in the mediation analyses, and age, sex, education and
injury time as covariates of no interest .
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Longitudinal analysis in CPTH

Changes of the acute serum biomarker related to the
pain symptom were compared over time from acute to
3 months post-injury within each group (mTBI + CPTH
and mTBI – CPTH groups), using the general linear
model of repeated measure analysis of variance (RMANOVA) respectively.
Statistical analysis

Statistical analysis was performed using the Statistical
Package SPSS version 20. The Shapiro-Wilk W test was
used to test for normality distribution of all continuous
variables. Logarithmic transformations were computed if
those variables that were not normally distributed (ie,
the inflammatory biomarkers). The independent twosample t-test and the Mann-Whitney test were used to
compare group differences based on data normality.
Chi-square analyses were applied to assess categorical
variables. Continuous variables were compared between
three groups using one-way analysis of variance
(ANOVA), Bonferroni’s post hoc test and KruskalWallis H Tests. P < 0.05 were considered to indicate a
significant difference. Between-group difference in both
acute and chronic post-injury GM volume abnormalities
was conducted using the general linear model in the
SPM12. Using a conjunction analysis [33], the different
subgroups of mTBI patients (with PTH and without
PTH) were compared to each other and to controls in
both acute and chronic phases respectively. Additionally,
the relationship between the GM volume for each identified ROI and pain measures were conducted using the
multivariate linear regression analysis after adjusting for
confounding covariates (age, sex, education and injury
time). For each model, pain symptom measurements (PVAS and HIT-6) were entered as dependent variables
and brain regions showing significant GMV group difference were entered as independent variables. This procedure was repeated for both initial and follow-up data,
and corrected for multiple comparisons using Bonferroni
correction.

Results
Demographic, clinical and neuropsychological measures

Demographic, behavioral and conventional MRI characteristics of the mTBI subgroups (for both initial and
follow-up stages) and HC participants were summarized
in the Table 1. In the acute phase (2.39 ± 1.47 days,
range: 0–6 days), a seventy-seven patients were divided
into two subgroups: 1) mTBI + APTH, 60 individuals
with APTH after mTBI, 2) mTBI – APTH, 17 individuals with mTBI without headache. Forty-two matched
healthy controls were recruited in the study. Fifty-four
patients (70.1%) from the original sample (mTBI +
CPTH: 15; mTBI – CPTH: 39) returned for their follow-
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up visit at 3 months post-injury (111.4 ± 22 days, range:
93–198). At follow-up, there were significant difference
between groups in years of age and education. Post-hoc
analysis further showed mTBI + CPTH was significantly
older than that of mTBI – CPTH (p = 0.007) and HCs
(p = 0.046). The years of education in the mTBI + CPTH
was lower than that of HCs (p = 0.017). Twenty-three
patients were excluded for refusing or indefinitely postponing follow-up request. 25% of mTBI + APTH patients converted to persistent PTH known as CPTH
during a follow-up 3 month post-injury.
In both acute and chronic stages, there were significant differences among the three groups for pain ratings
and impact of pain on patients’ lives, such as 5-item subscale of P-VAS scores and HIT-6 using Kruskal-Wallis
H Tests (p < 0.0001). Post-hoc analysis further showed
mTBI + APTH presented more pain complaints and
higher HIT-6 scores, compared with both mTBI –
APTH and HCs. Similarly, mTBI + CPTH also experienced more pain complaints and higher HIT-6 scores
than that of the mTBI – CPTH and HCs. Additionally,
mTBI + APTH group reported more PCS complaints
than that of the mTBI – APTH group (p = 0.007). Additionally, in comparison with the mTBI – CPTH group,
mTBI + CPTH group developed more PCS complaints
(p = 0.003). Other key clinical measurement of TBI severity showed no between-group differences in patients
(Table 2).
Global tissue volume changes

For both initial and follow-up stages, there were no significant differences in the total intracranial volume (p =
0.873; p = 0.825), gray matter volume (p = 0.283; p =
0.779), white matter volume (p = 0.067; p = 0.151), or
cerebrospinal fluid volume (p = 0.129; p = 0.799) among
these three groups (Table 1).
Regional GM volume abnormalities at acute post-injury
stage - effect of onset of PTH

For the ROI-based analysis, mTBI + APTH exhibited increased GM volume in the right ventrolateral prefrontal
cortex/orbitofrontal cortex (VLPFC/OFC), dorsal anterior cingulate cortex (dACC), dorsal posterior cingulate
cortex (dPCC), and bilateral parahippocampal gyrus
compared with both mTBI – APTH and HC groups
(Table 3 and Fig. 1). There was no significantly decreased GM volume of regions in the mTBI + APTH
groups. No other regions that fell outside a priori regions of interest was detected.
Regional GM volume abnormalities at chronic post-injury
stage - effect of PTH progression

The increased GM volumes in the dACC and dPCC
were still persistent in the mTBI + CPTH, while there
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Table 1 Demographic and clinical characteristic for acute/chronic mTBI subgroups and HC participants
P value*

HCs
n = 42

Acute phase
mTBI + APTH
n = 60

mTBI - APTH
n = 17

35.3 ± 11.2

37.47 ± 12.6

30.4 ± 12.8

Males (%)

21 (50%)

37 (61.7%)

Years of education

10.5 ± 5.2

0

P value+

Chronic phase
mTBI + CPTH
n = 15

mTBI - CPTH
n = 39

0.109

44.1 ± 12.8

32.8 ± 12.2

0.009e

8 (47%)

0.381

6 (40%)

24(61.6)

0.313

8.6 ± 4.0

9.0 ± 2.8

0.095

7.0 ± 4.8

9.2 ± 3.5

0.016f

4(1–10)

0

p < .0001a

2(1–4)

0

p < .0001g

Demographic
Age in years
C

Pain measurement
Present headache pain intensityK
HIT-6

36

48(36–68)

36

p < .0001

50(36–68)

36

p < .0001g

Present general pain intensityK

0

1(0–6)

0(0–4)

p < .0001a

0(0–2)

0(0-1)

p < .0001g

a

K

Average pain intensity

a

0

4(1–8)

0(0–4)

p < .0001

2(0–5)

0(0-4)

p < .0001g

0

0(0–8)

0(0–2)

p < .0001a

0(0–2)

0

p < .0001g

over the past weekK
Best pain intensityK
K

Worst pain intensity

0

6(2–10)

0(0–6)

p < .0001

4(0–6)

0(0-6)

p < .0001g

28A /23.5B

78.0

76.3

p < .0001b

81.7

62.6

p < .0001h

a

Neuropsychological ratings
PCL-CK
WAIS-III Coding

36.1 ± 15.8

33.7 ± 16.0

31.3 ± 13.8

p < .0001

33.7

50.8

p = .126

Trail Making A (s)

46.7 ± 16.8

61.1 ± 49

43.4 ± 32.0

0.118

68.7 ± 59.4

38.6 ± 22.3

p = .021i

Forward Digit Span

45.9 ± 33.1

10.2 ± 9.4

8.5 ± 2.8

0.358

7.7 ± 1.7

8.7 ± 1.5

p = .137

Backward Digit Span

8.3 ± 1.5

4.2 ± 2.1

4.2 ± 1.7

0.693

4.1 ± 1.9

4.6 ± 1.5

p = .623

Verbal Fluency Test

4.5 ± 2

14.8 ± 5.9

15.0 ± 4.8

0.003b

17.3 ± 7.0

17.8 ± 5.4

p = .668

5.2 ± 5.1

4.2 ± 4.5

p < .0001

5.8 ± 3.9

4.4 ± 2.5

p < .0005j

57.7

67.1

0.138

48.5

48.5

p=1

4.3 ± 3.7

p < .001

4.4 ± 4.3

2.9 ± 3.3

p = .008k

BDI-II
K

FSS
ISI

18.7 ± 6.4
A

B

60.5 /48.5
1.6 ± 2.3

7.3 ± 5.8

c

c

d

MRI characteristics
Total intracranial volume

1467.2 ± 149.4

1462.8 ± 141.4

1446.2 ± 119.1

0.873

1454.3 ± 153.9

1448.5 ± 115.1

0.825

Gray matter volume

631.7 ± 70.5

627.0 ± 64.9

602.4 ± 48.5

0.283

617.9 ± 49.9

627.0 ± 64.0

0.779

White matter volume

519.9 ± 66.9

508.5 ± 52.1

480.4 ± 57.8

0.067

505.9 ± 59.7

493.9 ± 51.1

0.151

Cerebrospinal fluid

314.8 ± 89.7

326.4 ± 106.2

374.5 ± 119.2

0.129

329.7 ± 94.3

327.0 ± 99.1

0.799

Mean ± standard deviation are reported. Sex is reported as frequencies. C Chi-square; K Kruskall Wallis (median (range) reported for pain measurement; mean ranks
reported for the other measurement); A Comparisons of mTBI + APTH, mTBI–APTH and HCs; B Comparisons of mTBI + CPTH, mTBI–CPTH and HCs
Abbreviations: HIT-6 Short Form Headache Impact Test, PCL-C PTSD Checklist – Civilian Version, WAIS Wechsler Adult Intelligence Scale – Third Edition, BDI-II the
Beck Depression Inventory- Second Edition, FSS Fatigue Severity Scale, ISI Insomnia Severity Index, mTBI + APTH mild traumatic brain injury and acute posttraumatic headache, mTBI–APTH mild traumatic brain injury without acute post-traumatic headache, HCs healthy controls, mTBI + CPTH mild traumatic brain injury
and chronic post-traumatic headache, mTBI–CPTH mild traumatic brain injury without chronic post-traumatic headache
* For comparisons among acute mTBI subgroups and HC participants. + For comparisons among chronic mTBI subgroups and HC participants
a
mTBI + APTH > mTBI – APTH, HCs; p < .0001
b
mTBI + APTH, mTBI – APTH > HCs; p < .005
c
mTBI + APTH, mTBI – APTH < HCs; p < .005
d
mTBI + APTH > HCs; p < .001
e
mTBI + CPTH > mTBI – CPTH, HCs; p < .05
f
mTBI + CPTH < HCs; p < .05
g
mTBI + CPTH > mTBI – CPTH, HCs; p < .0001
h
mTBI + CPTH, mTBI – CPTH > HCs; p < .0001
i
mTBI + CPTH > mTBI – CPTH; p < .05
j
mTBI + CPTH, mTBI – CPTH < HCs; p < .00005
k
mTBI + CPTH > HCs; p < .05

were also decreased GM volume in the right dorsolateral
prefrontal cortex/orbitofrontal cortex (DLPFC/OFC), in
comparison with both the mTBI – CPTH and HC
groups (Table 3 and Fig. 2). In addition, mTBI + CPTH

group also showed brain volume increase in the left primary motor cortex (M1) and cerebellum by using exploratory whole-brain analysis of GMV. The repeated
analyses with adding the BDI-II score as covariate at
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Table 2 Patients’s clinical data
Initial (acute phase)

mTBI + APTH

mTBI - APTH

P (2-tailed)

Duration after onset of mTBI, day

2.42 ± 1.45

2.29 ± 1.57

0.65

Duration of LOC (min)

9.70 ± 8.94

10.76 ± 12.96

0.78

Duration of PTA (h)

0.28 ± 1.01

0.18 ± 0.53

0.86

PCS (RPQ-6)

10.37 ± 6.95

5.59 ± 3.18

0.007

Follow-up (chronic phase)

mTBI + CPTH

mTBI - CPTH

P (2-tailed)

Duration after onset of mTBI, day

104 ± 12

114.1 ± 23.92

0.14

Duration of LOC (min)

7.9 ± 6.2

9.74 ± 10.2

0.433

Duration of PTA (h)

0.2 ± 0.56

0.15 ± 0.49

0.767

PCS (RPQ-6)

15 ± 7.09

8.13 ± 5.48

0.003

Mean ± standard deviation are reported. mTBI + APTH mild traumatic brain injury and acute post-traumatic headache, mTBI – APTH mild traumatic brain injury
without acute post-traumatic headache, mTBI + CPTH mild traumatic brain injury and chronic post-traumatic headache, mTBI –CPTH mild traumatic brain injury
without chronic post-traumatic headache, PCS Post concussive symptoms, RPQ Rivermead Post-Concussion Symptoms Questionnaire, LOC Loss of consciousness,
PTA Posttraumatic amnesia

Table 3 Regions showing significant GM volume changes at initial and follow-up among different subgroups of mTBI patients and
HCs
Comparisons

Findings

Cerebral regions

Area (Brodmann area) Cluster
size
Voxels

t

Peak
coordinate
x

y

z

Initial GM volume abnormalities (acute phase)
mTBI + APTH
vs
Control groupsa

Increased GM
volume

−20 −2

L, R Parahippocampal
gyrus

Parahippocampal (BA
35)

54

4.38 20

R Anterior cingulate

dACC (BA 32)

105

4.68 11

15

R Posterior cingulate

dPCC (BA 31)

47

4.07 6

−24 45

R Inferior frontal gyrus

VLPFC/OFC (BA 47, 10)

39

4.50 26

27

48

L Anterior cingulate

dACC (BA 32)

64

4.54 −
11

12

41

L Posterior cingulate

dPCC (BA 31)

78

4.47 −11 −
29

36

L Precentral gyrus

M1 (BA 4)

53

4.20 −18 −32 69

L Temporal gyrus

ITG (BA 20)

66

4.67 −59 −48 −15

L Cerebellar declive

–

65

5.14 −45 −59 −27

R Inferior frontal gyrus

DLPFC/OFC (BA9,10)

53

4.92 9

0

Follow-up GM volume abnormalities (chronic phase)
mTBI + CPTH vs Control
groupsb

mTBI + CPTH vs Control
groupsc

Increased GM
volume

Decreased GM
volume

59

33

Data were thresholded of P < 0.05 with FWE correction at the cluster level for multiple comparison. Peak coordinates refer to the MNI atlas
dACC dorsal anterior cingulate cortex, dPCC dorsal posterior cingulate cortex, VLPFC Ventrolateral prefrontal cortex, OFC Orbitofrontal cortex. M1 primary motor
cortex, ITG Inferior temporal gyrus, DLPFC Dorsolateral prefrontal cortex, mTBI + APTH Mild traumatic brain injury and acute post-traumatic headache, mTBI – APTH
Mild traumatic brain injury without acute post-traumatic headache, HCs Healthy controls. mTBI + CPTH mild traumatic brain injury and chronic post-traumatic
headache, mTBI – CPTH mild traumatic brain injury without chronic post-traumatic headache, FWE Family-wise error
a
Conjunction analysis of mTBI + APTH vs mTBI – CPTH and mTBI + APTH vs HCs corrected for age, sex, the white matter volume and total intracranial volume (p <
0.05, FWE corrected)
b
Conjunction analysis of mTBI + CPTH vs mTBI – CPTH and mTBI + CPTH vs HCs corrected for age, sex, the white matter volume and total intracranial volume (p <
0.05, FWE corrected)
c
Conjunction analysis of mTBI + CPTH vs mTBI – CPTH and mTBI – CPTH vs HCs corrected for age, sex, the white matter volume and total intracranial volume (p <
0.05, FWE corrected)
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Fig. 1 GM volume changes in mTBI + APTH. Areas showing GM volume changes in patients with mTBI + APTH, compared with HC and mTBI –
APTH groups (conjunction p < 0.05, FWE corrected), represented on a high-resolution T1-weighited template. Regions of increased GM volume
are represented in red (color-coded for their t value). dACC = dorsal anterior cingulate cortex, dPCC = dorsal posterior cingulate cortex, VLPFC =
ventrolateral prefrontal cortex, OFC = orbitofrontal cortex. mTBI + APTH = mild traumatic brain injury and acute post-traumatic headache, mTBI –
APTH = mild traumatic brain injury without acute post-traumatic headache, HCs = healthy controls

Fig. 2 GM volume changes in mTBI + CPTH. Areas showing GM volume changes in patients with mTBI + CPTH, compared with HC and mTBI –
CPTH groups (conjunction p < 0.05, FWE corrected), represented on a high-resolution T1-weighited template. Regions of increased GM volume
are represented in red (color-coded for their t value), and regions of decreased GM volume are shown in blue (color-coded for their t values).
dACC = dorsal anterior cingulate cortex, dPCC = dorsal posterior cingulate cortex, M1 = primary motor cortex, ITG = inferior temporal gyrus, DLPF
C = dorsolateral prefrontal cortex, OFC = orbitofrontal cortex. mTBI + CPTH = mild traumatic brain injury and chronic post-traumatic headache,
mTBI – CPTH = mild traumatic brain injury without chronic post-traumatic headache, HCs = healthy controls
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both acute and chronic post-injury stage yielded similar
results. Thus, the possible influence of depression level
on GM volume changes can be excluded.

HIT-6 scores. The independent factor was CCL2 levels,
and dependent variable was headache impact severity indicated by the HIT-6, with identified GM volume alterations as mediators. Results indicated that increased
volume in the dPCC partially mediated CCL2 level on
HIT-6 scores (Fig.3, mean [SE] indirect effect, 0.088
[0.0462], 95% CI, 0.01–0.164) in acute mTBI patients.

Regression analysis

Further regression analysis was restricted within the
clusters showing significant between-group differences
in the GMV for both acute and 3-month follow-up
(Table 3). During the acute stage, higher levels of HIT-6
were significantly correlated with increased GM volume
in the right dACC (β = 0.333, p = 0.005) and dPCC (β =
0.459, p = 0.001) in the whole mTBI cohort, while still
significant in the right dPCC (β = 0.389, P = 0.007) in
mTBI + APTH group. There was no correlation between
GMV and pain symptom measured by P-VAS and HIT6 at follow-up stage. Further, Serum biomarker was used
to build a stepwise regression model with pain symptom
measurement. Only higher CCL2 level in the acute stage
was associated with greater severity of HIT-6 scores in
the whole mTBI cohort during the acute phase and selected for further mediation analysis (p = 0.002, effect
size = 0.355) (Table 4). In addition, there were significant
differences among the three groups for acute CCL2 level
using one-way analysis of variance (ANOVA) (F (2,
116) = 3.165, p = 0.046). Post-hoc analysis further
showed that CCL2 was significantly elevated in mTBI +
APTH group, compared with mTBI–APTH group (p =
0.039). It indicated a nonstatistically significant trend of
increased CCL2 level in mTBI + APTH group, compared with the HCs group (p = 0.052). There was no
significant difference in CCL2 level between the mTBI–
APTH and HCs group (p = 0.534).

Longitudinal analysis of CPTH

The CCL2 level significantly increased from acute stage
to 3 months post-injury only in the mTBI + CPTH
group (F (1, 14) = 6.53, p = 0.023), but not in the mTBI
– CPTH group (F (1, 38) = 3.23, p = 0.08) (Fig. 4). In
addition, increased GMV of the dPCC and dACC in
acute PTH also exhibited persistent increases in mTBI +
CPTH group, compared with both mTBI – CPTH and
HC groups.

Discussion
The major findings were increased inflammation levels
accompanied by increased GMV of the dPCC and dACC
in mTBI patients with APTH, relative to both the control groups (mTBI – APTH and HCs). The inflammation effect on the headache impact was partially
mediated by the GMV of dPCC. Longitudinally, greater
upregulation in the CCL2 level accompanied by consistently increased GMV in the dPCC and dACC contributed to those patients who finally developed into the
CPTH.
The observed pattern of increased GMV differs from
some previous studies that commonly reported decreased GMV in pain-related disorders, partly due to the
fact that APTH patients experienced a traumatic exposure that can lead to both physical and psychological reactivity, and thus developed an adaptive anti-nociceptive
mechanism manifesting as regional hypertrophy in pain-

Mediation analysis

We tested whether GM volume (i.e. increased GM regions) mediates the association between CCL2 levels and
Table 4 Stepwise multiple regression analysis
Inflammatory
Level

Correlation
coefficient

T

P

Partial
correlation

Tolerance

VIF

a

CCL2

0.355

3.283

0.002

0.355

1.000

1.000

IL-1βb

0.015

0.139

0.890

0.016

1.000

1.000

IL-4b

0.010

0.093

0.927

0.011

0.999

1.001

IL-6b

− 0.106

−0.981

0.330

− 0.113

0.994

1.006

IL-8b

− 0.027

−0.185

0.854

− 0.022

0.542

1.843

IL-10b

0.025

0.229

0.819

0.027

0.991

1.009

b

IL-12

0.017

0.156

0.876

0.018

1.000

1.000

IFN-γb

0.038

0.347

0.730

0.040

0.999

1.001

0.032

0.291

0.772

0.034

1.000

1.000

TNF-α
a

b

Entered variables
b
Excluded variables
*p < .05
Outcome: HIT-6

*

Collinearity statistics
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Fig. 3 Mediation model. The relationship among CCL2 level, GMV of dPCC from conjunction analysis and HIT scores. Alteration of gray matter
volume in the dPCC mediates the relationship between CCL2 level and HIT scores in early mTBI patients. Covariates (age, sex, education, injury
time) were included in the model. Abbreviations: dPCC = dorsal posterior cingulate cortex; CCL2 = C-C motif chemokine ligand 2; HIT = short form
headache impact test

related areas [34]. Also, prior structural studies in PTH
were typically conducted on patients with chronic course
of headache, confirming that patients with persistent
PTH had significantly reduced grey matter volume
(GMV) or less cortical thickness [13, 35]. To our knowledge, it remained unknown that if brain morphologic
abnormality is associated with the acute onset of PTH.
Our findings indicated that acute brain trauma-related
headache (within 7 days) may shift the brain into a state
that fostered rapid defence mechanisms seen in increased GMV. Interestingly, the increased GMV pattern
was found in regions primarily located in the default
mode network (DMN), including dACC, dPCC and
parahippocampal gyrus. Our previous study had found
disruption of periaqueductal grey-DMN functional connectivity in APTH after mTBI. Thus, these findings

complement and extend existing literature by indicating
a potential structural basis for the disrupted functional
connectivity of the DMN involved in the antinociceptive
descending modulation network following mTBI [36].
Neuropsychological assessment showed that both the
mTBI + APTH and mTBI + CPTH groups reported
higher insomnia severity index (ISI) scores than HC
group, which support the notion that PTH has impacts
on sleep quality and can lead to poor recovery after
mTBI [37]. Correlation analysis further revealed that the
higher GMV in the right dACC and dPCC contributed
to the impact of PTH on the poorer quality of life. DMN
dysfunction has been reported to be involved in both
acute and chronic pain conditions, serving as a potential
biomarker for pain-related cognitive regulation (i.e., attention impairment) [38, 39]. Importantly, our previous

Fig. 4 CCL2 level changes at acute and chronic phase post-injury. The CCL2 level significantly increased between the acute and chronic phase
post-injury in the mTBI + CPTH group (*p < 0.05, repeated measures analysis of covariance [RM-ANCOVA]), but not in the mTBI – CPTH group
(p = 0.08, RM-ANCOVA). mTBI + CPTH = mild traumatic brain injury and chronic post-traumatic headache, mTBI – CPTH = mild traumatic brain
injury without chronic post-traumatic headache
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study have demonstrated that patients with APTH exhibit more attentions on injury-related pain symptoms
[20]. In the current study, mTBI + CPTH group showed
worse information processing speed (IPS) performance
indicated by higher Trail Making A scores than mTBI –
CPTH group, accompanying with the persistent GM increase in the dACC and dPCC, which can be engaged in
cognitive regulation [40]. These structural changes may
be coupled with alterations in the high-order brain areas
within the DMN in mTBI + APTH group [41], reflecting
the DMN dysfunction in pain cognitive modulation. It
also suggested that morphometric alterations can be an
appropriate parameter for monitoring PTH in the early
stage following mTBI.
The current study also provided some promising to
explore the cellular basis for such increased GMV. We
found that increased CCL2 level is an independent risk
for more headache impact on lives in patients with
mTBI. CCL2 is one of chemokines that increases rapidly
after various forms of experimental mTBI [42, 43], contributing to secondary brain damage through attracting
monocytes to sites of injury and inflammation [44].
Moreover, mTBI-induced disruption of the blood-brain
barrier (BBB) [45] allows the passage of inflammatory
cells out of the injured brain, and initiates to an elevated
systemic immune response to the genesis of nociceptor
hypersensitivity post-TBI [11]. Of particular interest is
the finding of macroscopic GM hypertrophy in the
dPCC (a core region in the DMN), which is related to
the arousal, self-reference and breadth of attention [40],
can mediate the contribution of circulating inflammatory
biomarker (i.e. CCL2 level) on pain impact severity during early stage after mTBI. This inflammation-brain
communication can be supported by the evidence that
astrocytes, which constitute 90% cortical tissue volume,
can be activated by proinflammatory cytokines released
in the early stage of inflammation and exhibit morphological changes (e.g. hypertrophy) [46, 47]. Thus, we
speculate that GM tissue cells can become hyperreactive by trauma-induced neuroinflammatory effect,
and then undergo plastic changes reflected by GMV increases. Unfortunately, VBM-based analysis was limited
to determine the specific histopathology underlying GM
macrostructural changes. Further study still need to explore the neural mechanism underpinning the bidirectional changes of GMV observed in the progression
of chronic PTH. Nevertheless, significant CCL2 rise over
time and GM volume increase in dPCC were found in
patients developing the CPTH, suggesting that the consistently observed associations of inflammation on PTH
were at least partially attributable to their effect on
GMV alternations. Taken together, the current study
highlighted the role of the circulating CCL2 level in the
pathogenesis and progression of PTH [48–50], and
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emphasized on the neuroinflammatory mechanism in
morphological alternations associated with pain modulation in cognitive domain.

Conclusions
In the current study, we demonstrated that GMV alteration can mediate the relationship between the inflammation and pain dysfunction following early mTBI, and
such regional change was primarily located within key
DMN region (dPCC). Our finding also held the possibility that both the significant upregulation of CCL2 level
and persistent GMV increase (dACC and dPCC) only in
the patients with CPTH and can be served as potential
predictors and targets of response for therapeutic
method.
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